The stone drug cider acid schonetinib capsules were removed from the net in Zhejiang Province.

On August 26, Zhejiang Pharmaceutical Procurement Platform issued an announcement: From now on, the company will withdraw the apple acid Schonetini capsules (specs: 12.5mg x 28 capsules/box) produced by Stone Pharmaceutical Group Euro-Italian Pharmaceutical Co., Ltd.
-malic acid Schoinigen is a multi-target subject Tyrosine kinase (RTKs) inhibitor developed by Pfizer that works by inhibiting tumor angiogenesty and anti-tumor cell production and metastasis.
the drug was approved in the United States in 2006 (the product is called Sunitinib) and entered the country in 2007 (the product is called Soltan), clinically used primarily for the treatment of gastrointestinal interstitioma, renal cell carcinoma and pancreatic neuroendocrine tumors.
Unitinib is the most common prescription drug approved in the United States for the treatment of advanced renal cell carcinoma, and its global sales have been rising year by year since its launch, peaking at about $1,236 million in 2012.
sunitinib sales have declined in recent years and are expected to fall by $1 billion in 2019.
in China, Sotan's performance is not bright, data show that in recent years Soltan in the domestic public medical institutions overall sales remained at more than 150 million yuan.
the drug was negotiated into the National Health Insurance Directory in 2018 at a price of $155 per pill, down from $438.16 previously, and was successfully renewed last year for 2019.
December 26, 2019, Stone Pharmaceutical Group 4 generic drugs Schoini capsules were approved for the first time in China (commodity name: Nolipin), Insight winning data show that Stone Pharmaceuticals in March this year, the online price of 107 yuan / tablet (12.5mg), has now covered at least 29 provinces and cities, the original study with the same specifications hanging online price is still 155 yuan / piece.
data source: Insight Database () According to insight database, Howson's cider acid Schonetini capsule was also approved on May 7, 2020, and has not yet been found to have a list price.
Zhejiang Province pharmaceutical procurement platform has not announced the specific reasons for the withdrawal of the stone pharmaceutical group of the species hanging network, there are understood peers can discuss in private.
.